Established care
Multidisciplinary rehabilitation stays the foundation
Physical, occupational, and speech therapy, medicines, orthotics, assistive technology, and selected surgery continue to support your child's function and participation.
Family-centered, evidence-guided care
Stem cell therapy for cerebral palsy in Istanbul, Turkey
A family-focused program combining cord blood or MSC protocols with rehabilitation, measurable goals, and full support for your Istanbul stay.
Conceptual biological visualization
Evidence status
What the evidence can support now
What we add
Cord blood and stromal cells
For eligible children, we offer defined IV cord-blood or MSC protocols with rehabilitation and pediatric monitoring built in.
What we won't promise
Reversal of the original brain injury
We will never promise a cure, normal development, or guaranteed walking, speech, or cognition gains from any infusion.
A direct answer
The short answer for families
We offer cord-blood and stromal-cell protocols alongside your child's rehabilitation team, matched to the exact cell source, dose, route, age, and GMFCS level that fits your child's case. This is an addition to your child's plan, not a substitute for it. Results vary between patients and stem cell therapy is not a guaranteed cure.
Start with the phenotype
Every child's cerebral palsy is different
The original brain disturbance is non-progressive, but movement, growth, pain, contractures, communication, and participation change over time — we plan around your child specifically.
Rehabilitation remains the foundation
Any regenerative option is integrated into your child's existing plan, never presented as a replacement for it.
- Goal-directed physical, occupational, speech, and feeding therapy
- Tone, pain, seizure, sleep, nutrition, and respiratory management
- Orthotics, mobility, communication, and other assistive technology
- Hip, spine, vision, hearing, dental, and growth surveillance
- Selected orthopedic or neurosurgical procedures when indicated
- 01
Motor subtype
Spastic, dyskinetic, ataxic, and mixed CP involve different movement patterns.
- 02
GMFCS level
Baseline gross-motor function strongly shapes realistic goals and measurement.
- 03
Associated needs
Epilepsy, vision, hearing, cognition, communication, swallowing, sleep, and respiratory health all matter.
- 04
Musculoskeletal change
Hip surveillance, scoliosis, contractures, pain, and growth need ongoing conventional care.
Product and route matter
Cell therapy is not one treatment
We never transfer a result across unrelated products and routes — your family gets the exact match for your child's case.
- 01
Autologous cord blood
The Duke randomized trial used each child's own stored cord blood by IV infusion.
Evidence boundaryThis result doesn't validate allogeneic MSCs, exosomes, or intrathecal delivery.
- 02
Allogeneic cord blood
Donor cord-blood products carry different immune, dose, and manufacturing considerations.
Evidence boundaryEvidence and eligibility differ from autologous products.
- 03
Mesenchymal stromal cells
Cord-tissue, bone-marrow, or other MSC products are studied in separate protocols.
Evidence boundaryWe match source, route, dose, and rehabilitation background to the evidence.
- 04
Intrathecal and exosome approaches
Some clinics offer spinal-fluid or acellular products.
Evidence boundaryThese add distinct procedure risks and aren't validated by an IV cord-blood trial — we explain this clearly.
Indexed evidence ledger
What the pediatric studies can and cannot say
Group averages don't predict one child's response. Dose, baseline function, natural development, rehabilitation, and measurement all shape interpretation.
01 Duke randomized cord-blood trial
Open study- Product
- Autologous cord blood by IV infusion
- Study design
- Randomized placebo-controlled study, 63 children
- Finding
- The primary randomized comparison did not show a mean GMFM-66 difference; a dose-associated exploratory signal was reported.
- Limitation
- Product and route are specific; exploratory dose findings don't support generic protocols.
02 Randomized crossover trial
Open study- Product
- Cell product studied in a small pediatric protocol
- Study design
- Randomized crossover study, 20 children
- Finding
- Contributed safety and feasibility data.
- Limitation
- No dramatic change in motor function and too small for broad prediction.
03 Systematic review and meta-analysis
Open study- Product
- Multiple cell sources and routes
- Study design
- Review of a limited, inconsistent evidence base
- Finding
- Suggested possible adjunctive motor signals in some studies.
- Limitation
- Heterogeneous protocols and small samples limit firm conclusions.
Measure what changes
We set two or three measurable goals together
Your family and rehabilitation team define practical goals before travel, so progress is measured, not assumed.
- 01
Gross motor function
GMFM-66 interpreted by trained clinicians against age and baseline trajectory.
- 02
Daily participation
PEDI-CAT, mobility, self-care, communication, school, and family-priority tasks.
- 03
Tone and comfort
Spasticity, dystonia, pain, sleep, care burden, and medication use.
- 04
Goal attainment
Two or three concrete goals measured by your home therapy team over time.
Clinical review before travel
A child-centered Istanbul evaluation
We start with your child's medical complexity, rehabilitation baseline, and your family's measurable goals to build the safest plan.
Records to send
- Neurology and developmental diagnosis, brain MRI, and birth or injury history
- CP subtype, GMFCS level, recent GMFM or therapy assessments
- Seizure, medication, swallowing, nutrition, respiratory, and sleep history
- Hip, spine, orthopedic, vision, hearing, and communication records
- Current physical, occupational, speech, feeding, and school supports
Reasons to pause
- Uncontrolled seizures, active infection, or respiratory instability
- Unresolved aspiration, nutrition, orthopedic pain, or urgent conventional-care need
- A route requiring sedation or lumbar puncture without appropriate pediatric hospital support
- Any promise of cure, normal development, or guaranteed walking, speech, or cognition
Transparent planning
Cerebral palsy stem cell therapy cost in Istanbul, Turkey
Your family quote names the exact product, route, pediatric hospital component, sedation if any, observation, accommodation, accessibility, and follow-up — and is never tied to a promised outcome.
For context, our general 2026 MSC planning range is $7,000-$18,000. Your child's multi-day pediatric plan is itemized separately after evaluation.
- Pediatric neurologic and rehabilitation review
- Exact cell product, source, dose, route, and release testing
- Hospital, anesthesia or sedation, monitoring, and accessibility needs
- Family accommodation, transfers, and home-team follow-up
Questions families ask us
- 01
How much does cerebral palsy stem cell therapy cost in Turkey?
- 02
Is the protocol autologous cord blood, donor cord blood, MSCs, another cell, or exosomes?
- 03
How many days will our family need to stay in Istanbul?
- 04
Which goals and validated measures will our home therapy team repeat?
FAQ
Questions about cerebral palsy
No, and we will never claim that. Our program studies whether specific products can support defined functions alongside rehabilitation. Results vary between patients and stem cell therapy is not a guaranteed cure.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.